Aarti Drugs

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE767A01016
NSEID: AARTIDRUGS
BSEID: 524348

INR

405.00

-2.85 (-0.7%)

BSENSE

Dec 05

BSE+NSE Vol: 1.58 lacs

{
  "main_header": {
    "sid": 657348,
    "name": "Aarti Drugs",
    "stock_name": "Aarti Drugs",
    "full_name": "Aarti Drugs Ltd",
    "name_url": "stocks-analysis/aarti-drugs",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "405.00",
    "chg": -2.85,
    "chgp": "-0.7%",
    "dir": -1,
    "prev_price": "407.85",
    "mcapval": "3,706.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524348,
    "symbol": "AARTIDRUGS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE767A01016",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.58 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aarti-drugs-657348-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Aarti Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-aarti-drugs-fallingrising-3739551",
        "imagepath": "",
        "date": "2025-12-02 00:37:19",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>The stock has underperformed significantly against the benchmark Sensex, which gained 0.87% over the past week, while Aarti Drugs declined by 3.31%. Over the last month, the divergence is even more pronounced, with the stock falling 15.19% compared to the Sensex’s 2.03% rise. Year-to-date, Aarti Drugs is down 9.67%, whereas the Sensex has advanced 9.60%. This underperformance extends over longer periods as well, with the stock posting negative returns over one, three, and five years, contrasting sharply with the Sensex’s robust gains.</p>\n<p>Today's trading session further emphasised the stock’s weakness. Aarti Drugs underperformed its sector by 1.8%, continuing a three-day losing streak that has resulted in a cumulative decline of ..."
      },
      {
        "title": "Aarti Drugs Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-technical-momentum-shifts-amid-mixed-market-signals-3737484",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AartiDrugs_technicaldot_3737484.png",
        "date": "2025-12-01 08:02:45",
        "description": "Aarti Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s current market dynamics."
      },
      {
        "title": "Is Aarti Drugs technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aarti-drugs-technically-bullish-or-bearish-3736476",
        "imagepath": "",
        "date": "2025-11-29 08:19:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Technical Trend and Price Movement</strong></p>\n<p>The latest technical assessment reveals that Aarti Drugs' trend has transitioned from mildly bullish to a sideways trajectory. This shift suggests a period of consolidation where neither buyers nor sellers dominate decisively. The stock closed at ₹425.40, slightly down from the previous close of ₹429.95, with intraday prices ranging between ₹424.10 and ₹431.75. Notably, the stock remains significantly below its 52-week high of ₹574.95, while comfortably above its 52-week low of ₹312.50, indicating a wide trading range over the past year.</p>\n<p><strong>Mixed Signals from Key Technical Indicators</strong></p>\n<p>Examining the Moving Average Convergence Divergence (MACD), a popular momentum indicator, reveals a divergence in weekly and ..."
      },
      {
        "title": "Aarti Drugs Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-technical-momentum-shifts-amid-mixed-indicator-signals-3732426",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AartiDrugs_technicaldot_3732426.png",
        "date": "2025-11-27 08:04:42",
        "description": "Aarti Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and volume-based metrics, reflecting a nuanced market assessment as the stock navigates recent price movements."
      },
      {
        "title": "Aarti Drugs Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-technical-momentum-shifts-amid-mixed-market-signals-3730277",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AartiDrugs_technicaldot_3730277.png",
        "date": "2025-11-26 08:05:05",
        "description": "Aarti Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This change is underscored by a complex interplay of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market assessment as the stock navigates recent price fluctuations."
      },
      {
        "title": "Aarti Drugs Experiences Mixed Financial Performance Amidst Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-stock-rating-downgraded-from-buy-to-hold-by-marketsmojo-3710747",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AartiDrugs_mojoScore_3710747.png",
        "date": "2025-11-18 08:25:48",
        "description": "Aarti Drugs, a small-cap pharmaceutical company, has undergone a recent evaluation adjustment. The firm reported a notable 45.33% increase in profit after tax, reaching Rs 99.19 crore, and maintains a strong return on capital employed. However, it faces challenges with long-term growth and has underperformed against benchmark indices."
      },
      {
        "title": "How has been the historical performance of Aarti Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-aarti-drugs-3708740",
        "imagepath": "",
        "date": "2025-11-17 23:03:31",
        "description": "Answer:\nThe historical performance of Aarti Drugs shows fluctuations in various financial metrics over the years.\n\nBreakdown:\nAarti Drugs' net sales have experienced a decline from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total operating income followed a similar trend, decreasing from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total expenditure, excluding depreciation, also decreased from INR 2,410.45 crore in March 2023 to INR 2,099.97 crore in March 2025, contributing to an operating profit (PBDIT) of INR 303.42 crore in March 2025, down from INR 307.79 crore in March 2023. Profit before tax showed a decline from INR 224.18 crore in March 2023 to INR 211.77 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore in March 2023 to INR 168.10 crore in March 2025. The consolidated net profit also saw a minor increase..."
      },
      {
        "title": "How has been the historical performance of Aarti Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-aarti-drugs-3693844",
        "imagepath": "",
        "date": "2025-11-12 23:15:30",
        "description": "Answer:\nThe historical performance of Aarti Drugs shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nAarti Drugs' net sales have shown a decline from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. This decline is mirrored in total operating income, which also decreased from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total expenditure, excluding depreciation, decreased from INR 2,410.45 crore in March 2023 to INR 2,099.97 crore in March 2025, contributing to an operating profit (PBDIT) of INR 303.42 crore in March 2025, down from INR 307.79 crore in March 2023. Profit before tax followed a similar trend, decreasing from INR 224.18 crore in March 2023 to INR 211.77 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore in March 2023 to INR 168.10 crore in March 2025. The company's total assets rose ..."
      },
      {
        "title": "Why is Aarti Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-aarti-drugs-fallingrising-3693459",
        "imagepath": "",
        "date": "2025-11-12 22:18:20",
        "description": "As of 12-Nov, Aarti Drugs Ltd is currently priced at 476.00, reflecting an increase of 1.35 (0.28%). The stock has underperformed its sector today by 0.7%, despite a significant rise in investor participation, with delivery volume increasing by 231.42% compared to the 5-day average. Over the past week, the stock has declined by 5.46%, and it has also shown a negative return of 7.99% over the past month. While the company has demonstrated high management efficiency with a return on capital employed (ROCE) of 15.44% and a low debt-to-equity ratio of 0.46, it faces challenges such as poor long-term growth, with operating profit declining at an annual rate of 5.65% over the last five years. Additionally, a decrease in promoter stake by 0.5% may indicate reduced confidence in the company's future.\n\nIn the broader market context, Aarti Drugs has consistently underperformed against the benchmark, with a return of ..."
      }
    ],
    "total": 645,
    "sid": "657348",
    "stock_news_url": "https://www.marketsmojo.com/news/aarti-drugs-657348"
  },
  "announcements": [
    {
      "details": "Disclosure under SEBI Takeover Regulations AARTIDRUGS : Seema Harshit Savla has submitted to the Exchange, vide letter dated November 21, 2019 a copy of disclosure under Regulation 10(6) in respect of acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.",
      "source": "NSE",
      "caption": "Aarti Drugs Limited - Disclosure under SEBI Takeover Regulations",
      "datetime": "22-Nov-2019"
    },
    {
      "details": "Aarti Drugs Limitedany namely Aarti Speciality Chemicals Limited CIN No: U24230MH2019PLC333306 on November 20, 2019.",
      "source": "NSE",
      "caption": "Aarti Drugs Limited - Acquisition",
      "datetime": "21-Nov-2019"
    },
    {
      "details": "Disclosure under SEBI Takeover Regulations AARTIDRUGS : Seema Harshit Savla has submitted to the Exchange vide letter dated November 07, 2019 a copy of Disclosure as per Regulation 10(5) of SEBI (SAST) Regulation 2011",
      "source": "NSE",
      "caption": "Aarti Drugs Limited - Disclosure under SEBI Takeover Regulations",
      "datetime": "08-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has declared <strong>10%</strong> dividend, ex-date: 04 Feb 25",
          "dt": "2025-02-04",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 30 Sep 20",
          "dt": "2020-09-30",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Aarti Drugs falling/rising?

2025-12-02 00:37:19

Recent Price Performance and Market Context

The stock has underperformed significantly against the benchmark Sensex, which gained 0.87% over the past week, while Aarti Drugs declined by 3.31%. Over the last month, the divergence is even more pronounced, with the stock falling 15.19% compared to the Sensex’s 2.03% rise. Year-to-date, Aarti Drugs is down 9.67%, whereas the Sensex has advanced 9.60%. This underperformance extends over longer periods as well, with the stock posting negative returns over one, three, and five years, contrasting sharply with the Sensex’s robust gains.

Today's trading session further emphasised the stock’s weakness. Aarti Drugs underperformed its sector by 1.8%, continuing a three-day losing streak that has resulted in a cumulative decline of ...

Aarti Drugs Technical Momentum Shifts Amid Mixed Indicator Signals

2025-12-01 08:02:45

Aarti Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s current market dynamics.

Is Aarti Drugs technically bullish or bearish?

2025-11-29 08:19:34

Recent Technical Trend and Price Movement

The latest technical assessment reveals that Aarti Drugs' trend has transitioned from mildly bullish to a sideways trajectory. This shift suggests a period of consolidation where neither buyers nor sellers dominate decisively. The stock closed at ₹425.40, slightly down from the previous close of ₹429.95, with intraday prices ranging between ₹424.10 and ₹431.75. Notably, the stock remains significantly below its 52-week high of ₹574.95, while comfortably above its 52-week low of ₹312.50, indicating a wide trading range over the past year.

Mixed Signals from Key Technical Indicators

Examining the Moving Average Convergence Divergence (MACD), a popular momentum indicator, reveals a divergence in weekly and ...

Aarti Drugs Technical Momentum Shifts Amid Mixed Indicator Signals

2025-11-27 08:04:42

Aarti Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and volume-based metrics, reflecting a nuanced market assessment as the stock navigates recent price movements.

Aarti Drugs Technical Momentum Shifts Amid Mixed Indicator Signals

2025-11-26 08:05:05

Aarti Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This change is underscored by a complex interplay of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market assessment as the stock navigates recent price fluctuations.

Aarti Drugs Experiences Mixed Financial Performance Amidst Changing Market Sentiment

2025-11-18 08:25:48

Aarti Drugs, a small-cap pharmaceutical company, has undergone a recent evaluation adjustment. The firm reported a notable 45.33% increase in profit after tax, reaching Rs 99.19 crore, and maintains a strong return on capital employed. However, it faces challenges with long-term growth and has underperformed against benchmark indices.

How has been the historical performance of Aarti Drugs?

2025-11-17 23:03:31

Answer: The historical performance of Aarti Drugs shows fluctuations in various financial metrics over the years. Breakdown: Aarti Drugs' net sales have experienced a decline from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total operating income followed a similar trend, decreasing from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total expenditure, excluding depreciation, also decreased from INR 2,410.45 crore in March 2023 to INR 2,099.97 crore in March 2025, contributing to an operating profit (PBDIT) of INR 303.42 crore in March 2025, down from INR 307.79 crore in March 2023. Profit before tax showed a decline from INR 224.18 crore in March 2023 to INR 211.77 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore in March 2023 to INR 168.10 crore in March 2025. The consolidated net profit also saw a minor increase...

How has been the historical performance of Aarti Drugs?

2025-11-12 23:15:30

Answer: The historical performance of Aarti Drugs shows a fluctuating trend in key financial metrics over the years. Breakdown: Aarti Drugs' net sales have shown a decline from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. This decline is mirrored in total operating income, which also decreased from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total expenditure, excluding depreciation, decreased from INR 2,410.45 crore in March 2023 to INR 2,099.97 crore in March 2025, contributing to an operating profit (PBDIT) of INR 303.42 crore in March 2025, down from INR 307.79 crore in March 2023. Profit before tax followed a similar trend, decreasing from INR 224.18 crore in March 2023 to INR 211.77 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore in March 2023 to INR 168.10 crore in March 2025. The company's total assets rose ...

Why is Aarti Drugs falling/rising?

2025-11-12 22:18:20

As of 12-Nov, Aarti Drugs Ltd is currently priced at 476.00, reflecting an increase of 1.35 (0.28%). The stock has underperformed its sector today by 0.7%, despite a significant rise in investor participation, with delivery volume increasing by 231.42% compared to the 5-day average. Over the past week, the stock has declined by 5.46%, and it has also shown a negative return of 7.99% over the past month. While the company has demonstrated high management efficiency with a return on capital employed (ROCE) of 15.44% and a low debt-to-equity ratio of 0.46, it faces challenges such as poor long-term growth, with operating profit declining at an annual rate of 5.65% over the last five years. Additionally, a decrease in promoter stake by 0.5% may indicate reduced confidence in the company's future. In the broader market context, Aarti Drugs has consistently underperformed against the benchmark, with a return of ...

View All News

Announcement

Aarti Drugs Limited - Disclosure under SEBI Takeover Regulations

22-Nov-2019 | Source : NSE

Disclosure under SEBI Takeover Regulations AARTIDRUGS : Seema Harshit Savla has submitted to the Exchange, vide letter dated November 21, 2019 a copy of disclosure under Regulation 10(6) in respect of acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aarti Drugs Limited - Acquisition

21-Nov-2019 | Source : NSE

Aarti Drugs Limitedany namely Aarti Speciality Chemicals Limited CIN No: U24230MH2019PLC333306 on November 20, 2019.

Aarti Drugs Limited - Disclosure under SEBI Takeover Regulations

08-Nov-2019 | Source : NSE

Disclosure under SEBI Takeover Regulations AARTIDRUGS : Seema Harshit Savla has submitted to the Exchange vide letter dated November 07, 2019 a copy of Disclosure as per Regulation 10(5) of SEBI (SAST) Regulation 2011